Xentria, Inc.
PrivateLast Round
Growth Equity
Oct 18, 2022
Total Funding Raised
$25M
Company Overview
Xentria, Inc. is a biopharmaceutical company that develops novel biologics and biosimilars for rare diseases, immunologic disorders, and oncology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Xentria, Inc. Comparables
Compare Xentria, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SarcoMed USA | 81% | |
| Roivant Sciences | 78% | |
| aTyr Pharma | 77% | |
Xentria, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Growth Equity | Oct 18, 2022 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 18, 2022
$25M raised in growth equity round.
Xentria, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Xentria, Inc.'s valuation, stock price, and market status.